| 名稱 | PD-L1 aAPC Cell IO細(xì)胞株 |
| 型號(hào) | CBP74164 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | PD-L1 aAPC Cell |
產(chǎn)品搜索
相關(guān)文章
- 從“腫瘤免疫療法”發(fā)展，看“單抗、CAR-T”任重而道遠(yuǎn)！
- TLR激動(dòng)劑藥物細(xì)胞篩選模型
- ATCC細(xì)胞株的特殊性質(zhì)或標(biāo)志必須在整個(gè)培養(yǎng)期間始終存在
- DKK-1細(xì)胞篩選模型
- 研究發(fā)現(xiàn)氣候可能決定人的鼻子形狀
- 科學(xué)家發(fā)現(xiàn)10個(gè)新的智力障礙易感基因
- 大腦中新發(fā)現(xiàn)的一種淋巴細(xì)胞，能夠清除大腦廢物
- 剛收到的細(xì)胞株如何進(jìn)行合理的處理？
- 【盤點(diǎn)】癌癥免疫檢查點(diǎn)療法的現(xiàn)狀與展望
- 耐藥ATCC細(xì)胞株如何構(gòu)建看完就會(huì)知道
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74164PD-L1 aAPC Cell IO細(xì)胞株
- 詳細(xì)內(nèi)容
| CBP74164 | |
| I. Background | |
| The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes. | |
| II. Introduction | |
| Expressed gene: | PDL1 |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+200ug/ml hygromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| III. Representative Data | |
Figure 1. Dose Response of Blocking Antibodies in PD-1/OX40 Dual Effector Reporter Cells (C22) With PD-L1 aAPC Cells. | |
會(huì)員_a.png)